What is RVMD stock forecast?

Revolution Medicines Inc forecast includes bull, base, and bear case scenarios from 2026 through 2030. Revenue and EPS projections are derived from analyst consensus and conservative extrapolation with growth deceleration for outer years.

RVMD

Revolution Medicines Inc

NASDAQ: RVMD · HEALTHCARE · BIOTECHNOLOGY

$140.55

-2.96% today

Updated 2026-04-29

Market cap

$29.88B

P/E ratio

—

P/S ratio

9,035.10x

EPS (TTM)

$-5.95

Dividend yield

—

52W range

$34 – $156

Volume

3.1M

Market cap

$29.88B

P/E ratio

—

P/S ratio

9,035.10x

EPS (TTM)

$-5.95

Dividend yield

—

52W range

$34 – $156

Volume

3.1M

Revolution Medicines Inc (RVMD) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

Price target summary

Current

$140.55

Consensus

$120.47

-14.29%

2030 Target

$152.58

+8.56%

DCF

—

Current price

$140.55

Analyst consensus

$120.47

-14.29%

2030 Target

$152.58

+8.56%

Intrinsic (DCF)

—

17 analysts:

9 Buy0 Hold0 Sell

Management guidance

Revolution Medicines has not provided specific revenue guidance for 2026-2030. The company is currently clinical-stage with limited product revenue ($742M TTM reflects non-recurring milestone payments, not product sales). Management expects to fund operations through 2027 with existing capital, suggesting significant burn rate. Revenue materialization depends entirely on clinical trial success for daraxonrasib and pipeline candidates.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

Revenue & price projection

Actual revenue Projected revenue Base case Bull to bear range

Bull case (2030)

$257.47

$2.6B Rev × 20x P/S

Base case (2030)

$152.58

$2.6B Rev × 12x P/S

Bear case (2030)

$104.90

$2.6B Rev × 8x P/S

Financial forecast — research-backed

Metric	2023	2024	2025	2026 (E)	2027 (E)	2030 (E)
Revenue	$0.0B	$0.0B	$0.0B	$0.1B	$0.3B	$2.6B
Revenue growth	—	-100.0%	—	-25.3%	408.7%	82.8%
EPS	$-3.77	$-3.57	$-5.91	$-7.47	$-6.48	$5.80
P/S ratio	—	—	—	12.0x	12.0x	12.0x
Implied price	—	—	—	$0.00	$19.07	$152.58

Catalysts & risks

Growth catalysts

+ Phase 3 RASolute 303 trial initiation for daraxonrasib in metastatic pancreatic cancer (PDAC) - first-line treatment evaluation

+ Phase 3 RASolute 302 interim data readout expected 2026-2027

+ Expansion of RAS(ON) platform with G12V-selective inhibitor (RMC-5127) and zoldonrasib clinical data presentations at AACR 2026

+ Potential FDA breakthrough therapy or accelerated approval designation if Phase 3 data supports

Key risks

- Clinical trial failure risk: Phase 3 RASolute 303 and 302 trials could fail to meet primary endpoints (PFS/OS), eliminating revenue upside

- Cash burn crisis: Company projects $1.03-1.09B net loss for 2025 alone; capital runway extends only to 2027 despite $2B+ market cap, requiring financing or M&A

- Competitive RAS inhibitor landscape: Sanofi acquired candidates, other biotech companies pursuing similar targets; market share concentration risk

- Merck deal collapse (Jan 2026) signals valuation/execution concerns; lack of near-term revenue until Phase 3 readout

Methodology

Revolution Medicines Inc's forward estimates are derived from AI-powered research synthesis combining analyst consensus from 17 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 7, 2026.